Characterization of N-glycan structures and biofunction of anti-colorectal cancer monoclonal antibody CO17-1A produced in baculovirus-insect cell expression system.

Advantages of the baculovirus insect cell expression system for production of recombinant proteins include high capacity, flexibility, and glycosylation capability. In this study, this expression system was exploited to produce anti-cancer monoclonal antibody (mAb) CO17-1A, which recognizes the antigen GA733. The heavy chain (HC) and light chain (LC) genes of mAb CO17-1A were cloned under the control of P(10) and Polyhedrin promoters in the pFastBac dual vector, respectively. Gene expression cassettes carrying the HC and LC genes were transposed into a bacmid in Escherichia coli (DH10Bac). The transposed bacmid was transfected to Sf9 insect cells to generate baculovirus expressing mAb CO17-1A. Confocal immunofluorescence and Western blot analyses confirmed expression of mAb CO17-1A in baculovirus-infected insect cells. The optimum conditions for mAb expression were evaluated at 24, 48, and 72 h after the virus infection at an optimum virus multiplicity of infection of 1. Expression of mAb CO17-1A in insect cells significantly increased at 72 h after infection. HPLC analysis of glycosylation status revealed that the insect-derived mAb (mAb(I)) CO17-1A had insect specific glycan structures. ELISA showed that the purified mAb(I) from cell culture supernatant specifically bound to SW948 human colorectal cancer cells. Fluorescence-activated cell sorting analysis showed that, although mAb(I) had insect specific glycan structures that differed from their mammalian counterparts, mAb(I) similarly interacted with CD64 (FcgammaRI) and Fc of IgG, compared to the interactions of mammalian-derived mAb. These results suggest that the baculovirus insect cell expression system is able to express, assemble, and secrete biofunctional full size mAb.

[1]  G. Barry,et al.  Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli , 1993, Journal of virology.

[2]  D. Jarvis,et al.  Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production. , 2003, Virology.

[3]  H. Maruyama,et al.  Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine , 2000, Cancer Immunology, Immunotherapy.

[4]  M. Herlyn,et al.  CO 17-1A and related monoclonal antibodies: their production and characterization. , 1986, Hybridoma.

[5]  N. Callewaert,et al.  High-throughput quantitative analysis of plant N-glycan using a DNA sequencer. , 2009, Biochemical and biophysical research communications.

[6]  Jared J. Aumiller,et al.  A fused lobes Gene Encodes the Processing β-N-Acetylglucosaminidase in Sf9 Cells* , 2008, Journal of Biological Chemistry.

[7]  S. Chamow,et al.  Therapeutic antibody expression technology. , 2001, Current opinion in biotechnology.

[8]  H. Kim,et al.  The glycosylation and in vivo stability of human granulocyte-macrophage colony-stimulating factor produced in rice cells. , 2008, Biological & pharmaceutical bulletin.

[9]  Kisung Ko,et al.  Glyco-engineering of biotherapeutic proteins in plants. , 2008, Molecules and cells.

[10]  M. Betenbaugh,et al.  Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in Trichoplusia ni Cells* , 1997, The Journal of Biological Chemistry.

[11]  I. Wilson,et al.  Core alpha1,3-fucose is a key part of the epitope recognized by antibodies reacting against plant N-linked oligosaccharides and is present in a wide variety of plant extracts. , 1998, Glycobiology.

[12]  D. Speicher,et al.  Immunogenicity of recombinant GA733‐2E antigen (CO17‐1A, EGP, KS1‐4, KSA, Ep‐CAM) in gastro‐intestinal carcinoma patients , 2001, International journal of cancer.

[13]  P. Kitts Construction of baculovirus recombinants , 2004, Cytotechnology.

[14]  M. Glogowska,et al.  Inhibition of tumor growth by plant-derived mAb. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Fleuren,et al.  Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model , 2004, Cancer Research.

[16]  D. Knebel-Mörsdorf,et al.  In Vitro Transcription of pe38/Polyhedrin Hybrid Promoters Reveals Sequences Essential for Recognition by the Baculovirus-Induced RNA Polymerase and for the Strength of Very Late Viral Promoters , 1998, Journal of Virology.

[17]  Jan Fagerberg,et al.  Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma , 1999, Cancer Immunology, Immunotherapy.

[18]  N. Kretchmer,et al.  Hyperinsulinaemia and impaired glucose tolerance in young Australian aborigines , 1990, The Lancet.

[19]  Yu-Chen Hu Baculovirus as a highly efficient expression vector in insect and mammalian cells , 2005, Acta Pharmacologica Sinica.

[20]  J. Bluestone,et al.  Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. , 1999, Cancer research.

[21]  R. L. Harrison,et al.  Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins. , 2006, Advances in virus research.

[22]  P. Hudson Recombinant antibody constructs in cancer therapy. , 1999, Current opinion in immunology.

[23]  M. Kieny,et al.  Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice , 2002, Cancer Gene Therapy.

[24]  P. Schlag,et al.  Quality of Recombinant Protein Determines the Amount of Autoreactivity Detected against the Tumor-Associated Epithelial Cell Adhesion Molecule Antigen: Low Frequency of Antibodies against the Natural Protein , 2005, The Journal of Immunology.

[25]  M. Little,et al.  Generation of recombinant antibodies , 1999, Molecular biotechnology.

[26]  S L Morrison,et al.  Effect of glycosylation on antibody function: implications for genetic engineering. , 1997, Trends in biotechnology.

[27]  Iain B. H. Wilson,et al.  Insect cells as hosts for the expression of recombinant glycoproteins , 1999 .

[28]  M. Glogowska,et al.  Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Hughes Pr,et al.  N-Linked glycosylation of a baculovirus-expressed recombinant glycoprotein in insect larvae and tissue culture cells , 1998 .

[30]  D. Iliopoulos,et al.  Anti-idiotypic antibodies to monoclonal antibody CO17-1A. , 1986, Hybridoma.

[31]  Eun-Yi Oh,et al.  Production of therapeutic proteins with baculovirus expression system in insect cell , 2008 .

[32]  F. Breedveld,et al.  Therapeutic monoclonal antibodies , 2000, The Lancet.

[33]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[34]  Arshad Jamal,et al.  Biological validation of plant-derived anti-human colorectal cancer monoclonal antibody CO17-1A. , 2009, Hybridoma.

[35]  J. Tjandra,et al.  Development of human anti‐murine antibody (HAMA) response in patients , 1990, Immunology and cell biology.

[36]  C. Strassburg,et al.  Baculovirus recombinant expressing a secreted form of a transmembrane carcinoma-associated antigen. , 1992, Cancer research.

[37]  M. Herlyn,et al.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. , 1980, Cancer research.

[38]  T. Yokoyama,et al.  Expression of biologically active recombinant equine interferon-gamma by two different baculovirus gene expression systems using insect cells and silkworm larvae. , 2002, Cytokine.